Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Philippe FayemendyBenoît MarinAnaïs LabrunieYves BoirieStéphane WalrandNajate AchamrahMoïse CoëffierPierre-Marie PreuxGéraldine LautretteJean-Claude DesportPhilippe CouratierPierre Jésus
• Organismes : Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Plate forme de bioinformatique et biostatistique Laboratoire de Biostatistique et d'Informatique Médicale Plate forme de bioinformatique et biostatistique Neuroépidémiologie Tropicale Centre de Recherche en Nutrition Humaine d'Auvergne Unité de Nutrition Humaine Unité de Nutrition Humaine Centre de Recherche en Nutrition Humaine d'Auvergne Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau Service de Nutrition [CHU Rouen] Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau Service de Nutrition [CHU Rouen] Neuroépidémiologie Tropicale Service de l'Information Médicale et de l'Évaluation [CHU Limoges] Service de Neurologie [CHU Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service de Neurologie [CHU Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges]
• Publié dans Journal of the Neurological Sciences le 27/10/2020

---

Résumé : RationaleHypermetabolism (HM) in Amyotrophic lateral sclerosis (ALS) is the reflection of a high energy metabolic level, but this alteration seems controversial. The main objective of the study was to confirm the existence of HM during ALS compared to healthy subjects.MethodsA cohort of ALS patients was compared to a control group without metabolic disorder. The assessment included anthropometric criteria measurements, body composition by bioelectric impedance analysis and resting energy expenditure (REE) by indirect calorimetry. HM was defined as a variation > +10% between measured and calculated REE. Statistical analysis used Mann-Withney and Chi2 tests. Multivariate analysis included logistic regression.Results287 patients and 75 controls were included. The metabolic level was higher in ALS patients (1500 kcal/24 h [1290–1693] vs. 1230 kcal/24 h [1000–1455], p < 0.0001) as well as the REE/fat free mass ratio (33.5 kcal/kg/24 h [30.4–37.8] vs. 28.3 kcal/kg/24 h [26.1–33.6], p < 0.0001). 55.0% of ALS patients had HM vs. 13.3% of controls (p < 0.0001). HM was strongly and positively associated with ALS (OR = 9.50 [4.49–20.10], p < 0.0001).ConclusionsHM in ALS is a reality, which affects more than half of the patients and is associated with ALS. This work confirms a very frequent metabolic deterioration during ALS. The identification of HM can allow a better adaptation of the patients' nutritional intake.

---

Fichiers liés : S0022510X20305931.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Déborah DucasseJonathan DuboisIsabelle JaussentJean‐michel AzorinB EtainSébastien GardChantal HenryThierry BougerolJean‐pierre KahnValérie AubinFrank BellivierRaoul BelzeauxCaroline DubertretJulien DubreucqPierre‐michel LlorcaJosephine LoftusChristine PasserieuxMircea PolosanLudovic SamalinMarion LeboyerAntoine YrondiDjamila BennabiEmmanuel HaffenJulia MaruaniEtienne AllauzeVincent CamusThierry A. d'AmatoOlivier DoumyJérôme HoltzmannChristophe LançonFanny MoliereRémi MoirandRaphaëlle Marie RichieriMathilde HornL. SchmittFlorian StephanJean‐baptiste GentyGuillaume VaivaMichel WalterWissam El-HageBruno AouizerateÉmilie OliéPhilippe Courtet
• Organismes : Institut Pascal Service Psychiatrie et psychologie médicale [CHU Toulouse] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier]
• Publié dans Depression and Anxiety le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Thi Loi Daovan Thuan HoangAmal MagmounTran Duc Anh LySophie Alexandra BaronLinda HadjadjNaomie CanardTassadit DraliFrédérique GourietDidier RaoultPhilippe ParolaPierre MartyJean-Marc RolainPhilippe Gautret
• Organismes : Microbes Evolution Phylogénie et Infections Microbes Evolution Phylogénie et Infections Microbes Evolution Phylogénie et Infections Microbes Evolution Phylogénie et Infections Vecteurs - Infections tropicales et méditerranéennes Microbes Evolution Phylogénie et Infections Vecteurs - Infections tropicales et méditerranéennes
• Publié dans Travel Medicine and Infectious Disease le 25/10/2020

---

Fichiers liés : S1477893920304373.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Jean-Pierre DelordAntoine ItalianoAhmad AwadaPhilippe AftimosNadine HouédéCéleste LebbéCeline PagesThierry LesimpleMonica DinulescuJan SchellensSuzanne LeijenSylvie RotteyVibeke KruseRichard KeffordSandrine FaivreCarlos Alberto Gomez-RocaArmin ScheulerGiorgio MassiminiEric Raymond
• Organismes : Institut Universitaire du Cancer de Toulouse - Oncopole Institut Bergonié [Bordeaux] Université de Bordeaux Institut Jules Bordet [Bruxelles] Institut Jules Bordet [Bruxelles] Institut de Cancérologie du GARD ICG - CHU Nîmes Immunologie humaine, physiopathologie & immunothérapie CIC Saint Louis Immunologie humaine, physiopathologie & immunothérapie CIC Saint Louis CRLCC Eugène Marquis Service de Dermatologie [Rennes] = Dermatology [Rennes] Netherlands Cancer Institute Utrecht Institute for Pharmaceutical Sciences Netherlands Cancer Institute Ghent University Hospital Heymans Institute of Pharmacology Ghent University Hospital Heymans Institute of Pharmacology Macquarie University [Sydney] Melanoma Institute Australia [Sydney, NSW, Australia] Hôpital Beaujon [AP-HP] Institut Universitaire du Cancer de Toulouse - Oncopole EMD Serono Research & Development Institute Merck [Darmstadt] Hôpital Beaujon [AP-HP]
• Publié dans Targeted Oncology le 01/11/2020

---

Résumé : The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-competitive MEK1/2 inhibitor. Objective: Our objectives were to describe the results of a phase I, first-in-human, dose-escalation trial of pimasertib that investigated the maximum tolerated dose, recommended phase II dose, and safety, as well as other endpoints. Patients and methods: Four dosing schedules of pimasertib (once daily [qd], 5 days on, 2 days off; qd, 15 days on, 6 days off; continuous qd; continuous twice daily [bid]) were evaluated in patients with advanced solid tumors. Each treatment cycle lasted 21 days. The primary objective was to determine the maximum tolerated dose based on dose-limiting toxicities (DLTs) evaluated during cycle 1, and the recommended phase II dose (RP2D). Secondary objectives included safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Results: Overall, 180 patients received pimasertib (dose range 1-255 mg/day). DLTs were mainly observed at doses ≥ 120 mg/day and included skin rash/acneiform dermatitis and ocular events, such as serous retinal detachment. The most common drug-related adverse events were consistent with class effects, including diarrhea, skin disorders, ocular disorders, asthenia/fatigue, and peripheral edema. The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules. Pimasertib decreased ERK phosphorylation within 2 h of administration, which was maintained for up to 8 h at higher doses and prolonged with bid dosing. Conclusions: Based on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedule and the RP2D was defined as 60 mg bid.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : John B WhitfieldS MassonSuthat LiangpunsakulSebastian MuellerGuruprasad P AithalFlorian EyerDermot GleesonA ThompsonFelix StickelMichael SoykaAnn K DalyHeather J CordellTatiana ForoudLawrence LumengMunir PirmohamedBertrand NalpasJean-Marc JacquetRomain MoirandPierre NahonSylvie S. NaveauPascal PerneyPaul S HaberHervé SeitzC DayPhilippe MathurinTimothy R MorganDevanshi Seth
• Organismes : QIMR Berghofer Medical Research Institute Newcastle University [Newcastle] Indiana University System Universität Heidelberg [Heidelberg] = Heidelberg University University of Nottingham, UK Technische Universität Munchen = Technical University Munich = Université Technique de Munich Royal Hallamshire Hospital University of Liverpool University hospital of Zurich [Zurich] University-Hospital Munich-Großhadern [München] Newcastle University [Newcastle] Newcastle University [Newcastle] Indiana University School of Medicine Indiana University System University of Liverpool Hôpital Universitaire Carémeau [Nîmes] Hôpital Universitaire Carémeau [Nîmes] Nutrition, Métabolismes et Cancer Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Génomique Fonctionnelle des Tumeurs Solides Hôpital Jean Verdier [AP-HP] AP-HP - Hôpital Antoine Béclère [Clamart] Hôpital Universitaire Carémeau [Nîmes] The University of Sydney Universität Heidelberg [Heidelberg] = Heidelberg University Newcastle University [Newcastle] Centre Hospitalier Régional Universitaire [CHU Lille] California State University [Long Beach] University of California The University of Sydney
• Publié dans The American Journal of Gastroenterology le 22/10/2020

---

Résumé : Introduction - Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist in discovery of mechanisms and prediction of risk. Methods - We conducted a multicenter case-control study (GenomALC) comparing 1,293 cases (with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol exposure but no evidence of liver disease, 73.6% male). Information confirming or excluding cirrhosis, and on alcohol intake and other potential risk factors, was obtained from clinical records and by interview. Case-control differences in risk factors discovered in the GenomALC participants were validated using similar data from 407 cases and 6,573 controls from UK Biobank. Results - The GenomALC case and control groups reported similar lifetime alcohol intake (1,374 vs 1,412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1,288) vs 6.5% (48/734), P = 2.27 × 10) and higher premorbid body mass index (26.37 ± 0.16 kg/m) than controls (24.44 ± 0.18 kg/m, P = 5.77 × 10). Controls were significantly more likely to have been wine drinkers, coffee drinkers, smokers, and cannabis users than cases. Cases reported a higher proportion of parents who died of liver disease than controls (odds ratio 2.25 95% confidence interval 1.55-3.26). Data from UK Biobank confirmed these findings for diabetes, body mass index, proportion of alcohol as wine, and coffee consumption. Discussion - If these relationships are causal, measures such as weight loss, intensive treatment of diabetes or prediabetic states, and coffee consumption should reduce the risk of alcohol-related cirrhosis.

---

Fichiers liés : Whitfield et al. - 2021 - Obesity, Diabetes, Coffee, Tea, and Cannabis Use A.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Mathieu ChalouniStanislas PolPhilippe SogniHélène FontaineKarine LacombeJean Marc-LacombeLaure EsterleCeline DorivalMarc BourlièreFirouzé Bani-SadrVictor de LedinghenDavid ZucmanDominique LarreyDominique Salmon-CéronFabrice CarratLinda Wittkop
• Organismes : Team MORPH3EUS CIC Bordeaux Immunité Innée - Innate Immunity Hôpital Cochin [AP-HP] Immunité Innée - Innate Immunity Hôpital Cochin [AP-HP] Immunité Innée - Innate Immunity Hôpital Cochin [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] INSERM-TRANSFERT [Paris] Team MORPH3EUS Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Saint-Joseph [Marseille] Hôpital universitaire Robert Debré [Reims] Bordeaux Research In Translational Oncology [Bordeaux] Hôpital Haut-Lévêque [CHU Bordeaux] Hôpital Foch [Suresnes] Hôpital Saint-Éloi [Montpellier] Hôpital Cochin [AP-HP] Hôpital Hôtel-Dieu [Paris] Université Paris Cité Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Institut de Santé Publique, d'Epidémiologie et de Développement Team MORPH3EUS CIC Bordeaux
• Publié dans Journal of Hepatology le 23/10/2020

---

Résumé : Background & aims: Direct-acting antivirals (DAA) lead to high sustained virological response (SVR) rates and decrease the risk of disease progression. We compared SVR rates and all-cause, liver- and non-liver-related deaths, liver-related events, and non-liver-related cancers in HIV/HCV-coinfected and HCV-monoinfected participants from 2 French cohort studies after initiation of DAA treatment. Methods: Up to 4 HCV-monoinfected participants from the ANRS CO22 HEPATHER cohort were matched by age and sex to each HIV/HCV-coinfected patient from the ANRS CO13 HEPAVIH cohort; both are nationwide, prospective, multicentre, and observational. Participants were initiated on DAAs between March 2014 and December 2017. Cox proportional hazards models adjusted by age, sex, duration since HCV diagnosis, HCV transmission routes, HCV genotypes, cirrhosis, tobacco, alcohol consumption, and SVR (time dependent) were used. Results: A total of 592 HIV/HCV-coinfected and 2,049 HCV-monoinfected participants were included; median age was 53.3 years (inter-quartile range: 49.6-56.9) and 52.9 years (49.6; 56.7), 1,498 (73.1%) and 436 (73.6%) were men, and 159 (28.8%) and 793 (41.2%) had cirrhosis, respectively. SVR was observed in 92.9% and 94.6%, respectively. HIV coinfection was associated with higher risk of all-cause death (hazard ratio [HR] 1.93; 95% CI 1.01-3.69), non-liver-related death (HR 2.84; 95% CI 1.27-6.36), and non-liver-related cancer (HR 3.26; 95% CI 1.50-7.08), but not with liver-related-death (HR 1.04; 95% CI 0.34-3.15) or liver-related events (HR 0.66; 95% CI 0.31-1.44). Conclusions: After DAA treatment, HIV-coinfected individuals had similar SVR rates and risk of liver-related deaths and events compared with HCV-monoinfected individuals, but had a higher risk of all-cause and non-liver-related deaths and non-liver-related cancers. Lay summary: We compared the risk of several clinical events in participants infected by human immunodeficiency virus and hepatitis C virus with those infected with hepatitis C virus alone, matched on age and sex, after treatment with contemporary direct-acting antivirals. We found a higher risk of all-cause deaths, non-liver-related deaths, and non-liver-related cancers in participants coinfected with the human immunodeficiency virus and hepatitis C virus, and no differences for the risk of liver-related deaths or events. Trial registration: ClinicalTrials.gov NCT03324633 NCT01953458.

---

Fichiers liés : inserm-03332406.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Sophie MathaisXavier MoissetBruno PereiraFrederic TaitheJonathan CironPierre M LabaugeCécile DulauDavid-Axel LaplaudJérôme de SèzeJean PelletierEric BergerChristine Lebrun-FrénayGiovanni CastelnovoGilles EdanGilles DeferPatrick VermerschBertrand BourreJean-Philippe CamdessanchéLaurent MagyA.-M. GuennocGuillaume MatheyThibault MoreauOlivier GoutO HeinzlefElisabeth MaillartSandra VukusicPierre Clavelou
• Organismes : CHU Clermont-Ferrand Neuro-Dol CHU Clermont-Ferrand CHU Clermont-Ferrand CHU Clermont-Ferrand Département de Neurologie [Toulouse] CHU Montpellier = Montpellier University Hospital Université de Montpellier Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale CIC Bordeaux Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CIC - Nantes Centre de Recherche en Transplantation et Immunologie CIC Strasbourg Service de Neurologie [Strasbourg] Assistance Publique - Hôpitaux de Marseille Service de Neurologie [CHRU Besançon] Hôpital Pasteur [Nice] Centre Hospitalier Universitaire de Nice Service de Neurologie [CHU Nimes] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Service de Neurologie [CHU Caen] Centre Hospitalier Régional Universitaire [CHU Lille] Lille Neurosciences & Cognition - U 1172 CHU Rouen Service de Neurologie [CHU de Saint-Étienne] Service de Neurochirurgie [CHU Limoges] Service de neuroradiologie [Tours] Maladies chroniques, santé perçue, et processus d'adaptation Service de neurologie [CHRU Nancy] Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Service de Neurologie [CHU de Poissy] CHU Pitié-Salpêtrière [AP-HP] Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Université Claude Bernard Lyon 1 Neuro-Dol CHU Clermont-Ferrand
• Publié dans Neurotherapeutics le 01/11/2020

---

Résumé : High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Several reports have suggested that HDB treatment may be associated with an increased risk of relapse. We aimed to determine whether HDB increases the risk of clinical relapse in PMS and describe the characteristics of the patients who experience it. We conducted a French, multicenter, retrospective study, comparing a group of PMS patients treated with HDB to a matched control group. Poisson regression was applied to model the specific statistical distribution of the annualized relapse rate (ARR). A propensity score (PS), based on the inverse probability of treatment weighting (IPTW), was used to adjust for indication bias and included the following variables: gender, primary PMS or not, age, EDSS, time since the last relapse, and co-prescription of a DMT. Two thousand six hundred twenty-eight patients treated with HDB and 654 controls were analyzed with a follow-up of 17 +/- 8 months. Among them, 148 validated relapses were observed in the group treated with biotin and 38 in the control group (p = 0.62). After adjustment based on the PS, the ARR was 0.044 +/- 0.23 for the biotin-treated group and 0.028 +/- 0.16 for the control group (p = 0.18). The more relapses there were before biotin, the higher the risk of relapse during treatment, independently from the use of HDB. While the number of relapses reported for patients with no previous inflammatory activity receiving biotin has gradually increased, the present retrospective study is adequately powered to exclude an elevated risk of relapse for patients with PMS treated with HDB.

---

Fichiers liés : Mathais et al-2020-Relapses in Patients Treated with High-Dose Biotin.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Stanislas Grassin DelyleCamille RoquencourtPierre MoineGabriel SaffroyStanislas CarnNicholas HemingJérôme FleurietHélène SalvatorEmmanuel NalineLouis-Jean CoudercPhilippe DevillierEtienne A ThévenotDjillali Annane
• Organismes : Service de pneumologie [Hôpital Foch] Infection et inflammation Laboratoire Sciences des Données et de la Décision (CEA, LIST) Hôpital Raymond Poincaré [AP-HP] Infection et inflammation Hôpital Raymond Poincaré [AP-HP] Hôpital Raymond Poincaré [AP-HP] Hôpital Raymond Poincaré [AP-HP] Infection et inflammation Hôpital Raymond Poincaré [AP-HP] Service de pneumologie [Hôpital Foch] Service de pneumologie [Hôpital Foch] Service de pneumologie [Hôpital Foch] Service de pneumologie [Hôpital Foch] Service de Pharmacologie et Immunoanalyse Médicaments et Technologies pour la Santé Hôpital Raymond Poincaré [AP-HP] Infection et inflammation
• Publié dans EBioMedicine le 28/10/2020

---

Résumé : Background Early diagnosis of coronavirus disease 2019 (COVID-19) is of the utmost importance but remains challenging. The objective of the current study was to characterize exhaled breath from mechanically ventilated adults with COVID-19. Methods In this prospective observational study, we used real-time, online, proton transfer reaction time-of-flight mass spectrometry to perform a metabolomic analysis of expired air from adults undergoing invasive mechanical ventilation in the intensive care unit due to severe COVID-19 or non-COVID-19 acute respiratory distress syndrome (ARDS). Findings Between March 25th and June 25th, 2020, we included 40 patients with ARDS, of whom 28 had proven COVID-19. In a multivariate analysis, we identified a characteristic breathprint for COVID-19. We could differentiate between COVID-19 and non-COVID-19 ARDS with accuracy of 93% (sensitivity: 90%, specificity: 94%, area under the receiver operating characteristic curve: 0•94-0•98, after cross-validation). The four most prominent volatile compounds in COVID-19 patients were methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal. Interpretation The real-time, non-invasive detection of methylpent-2-enal, 2,4-octadiene 1-chloroheptane, and nonanal in exhaled breath may identify ARDS patients with COVID-19.

---

Fichiers liés : OpenAccess_StanislasGrassinDelyle.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Diane BruyèreFranck MonnienPrudence ColpartPatrick RoncaratiLucine VuittonElodie HendrickAlexis LepinoyAlexandra LuquainCharlotte PilardThomas LerhoChloé MolimardPhilippe MaingonLaurent ArnouldMarie-Christine Bone-LepinoyLaurence DusserreLaurent MartinCelia ReyndersMarie AncionDidier PeiffertAgnès LerouxPascale HubertJean-Baptiste DelhormeJean-Pierre GhnassiaAnne-Sophie WoronoffPhilippe DelvenneJ.L. PretetJean-François BossetOlivier PeulenChristiane MouginSéverine Valmary-DeganoMichael Herfs
• Organismes : GIGA Institute [Université de Liège] Service d'Oncologie Médicale [CHRU Besançon] Groupe Interdisciplinaire de Génoprotéomique Appliquée Centre Hospitalier Régional Universitaire de Besançon GIGA Institute [Université de Liège] Service d'Oncologie Médicale [CHRU Besançon] Service de Pathologie [CHU de Dijon] Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)
• Publié dans Modern Pathology le 23/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/2021
• Auteurs : Nicolas PaponGilles NevezSolene Le GalCecile VigneauFlorence Robert-GangneuxJean-Philippe BoucharaOliver A. CornelyDavid W. DenningJean-Pierre Gangneux
• Organismes : SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Groupe d'Étude des Interactions Hôte-Pathogène SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Centre Hospitalier Régional Universitaire de Brest Groupe d'Étude des Interactions Hôte-Pathogène Centre Hospitalier Régional Universitaire de Brest SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Groupe d'Étude des Interactions Hôte-Pathogène Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Groupe d'Étude des Interactions Hôte-Pathogène Centre Hospitalier Universitaire d'Angers SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques German Centre for Infection Research University Hospital of Cologne [Cologne] Global action fund for fungal infections [Geneva] Manchester Academic Health Science Centre Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
• Publié dans The Lancet Microbe le 11/12/2020

---

Fichiers liés : Papon-2021-Fungal infections in transplant recipients.pdf

---

Source